Science 1st - Neuroscience: Out with the Old, In with the New
Science 1st - Neuroscience: Out with the Old, In with the New
JLABS @LabCentral , 700 Main Street , Cambridge , MA 02139
May 14, 2015 from 16:00 PM to 18:30 PM (EDT)
$10 - $35
The challenges of neuroscience R&D have been vexing pharmas and investors for years, with little to show for it. Is now the time to walk away from neuroscience research and wait on the sidelines for advancements to come? Or should investors and companies capitalize now, while the science is rapidly advancing, with fewer players and more potential for opportunity?
Johnson & Johnson Innovation, JLABS (JLABS) is bringing in the experts from all areas of neuroscience to discuss the challenges, opportunities, arrivals and departures in our field. Hear from folks who are heavily invested in neuroscience, as well as folks who have decided to back away.
2:00pm | Registration
2:30pm | Presentations
3:15pm | Panel discussion
3:45pm | Reception
4:30pm | Close
Elliot Ehrich, M.D. | Executive Vice President, Research and Development, and Chief Medical Officer, Alkermes read bio»
Philip Iredale | Head of Business Research, Neuroscience and Pain Research Unit, Pfizer, Inc. read bio»
Michal Preminger, Ph.D., MBA | | Executive Director, Harvard University Office of Technology Development read bio»
[moderator] Jeffrey Nye, M.D., Ph.D. | Vice President Neuroscience Innovation and Scientific Partnership Strategy, Johnson & Johnson Innovation read bio»
$25 | General Public
$15 | Student/Academic
$35 | At the door
700 Main St
Cambridge, MA 02139
About the Science First series:
The purpose of the Science First series, sponsored by Johnson & Johnson Innovation, JLABS, is to bring together top experts to explore a pressing topic in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.
Elliot Ehrich, M.D. | Executive Vice President, Research and Development, and Chief Medical Officer, Alkermes
Elliot Ehrich, M.D., leads the discovery, delivery science, research and development, project management and medical affairs functions at Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., overseeing the successful clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. He also serves on the Scientific Advisory Board of Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies.
Dr. Ehrich was a Phi Beta Kappa graduate of Princeton University, where he received a Bachelor of Arts degree in biochemistry. He worked as a research associate at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and later earned his medical degree from Columbia University, College of Physicians and Surgeons. At Stanford University, Dr. Ehrich completed a residency in internal medicine and a clinical fellowship in the Department of Immunology and Rheumatology. He was subsequently a postdoctoral research fellow at the Howard Hughes Medical Institute at Stanford University School of Medicine, in the Department of Microbiology and Immunology.
Connect with Elliot:
Philip Iredale, Ph.D. | Head of Business Research, Neuroscience and Pain Research Unit, Pfizer, Inc.
Phil did his Ph.D. and a brief post doc in signal transduction mechanisms in CNS at the University of Nottingham in the UK. In 2004 he joined the Duman/Nestler lab at Yale investigating the molecular regulation of CRF receptors and, exploring the role the receptor plays in withdrawal from drugs of abuse. He joined Pfizer in 1997 as lab head where he initiated and eventually led a CB1 antagonist program for the treatment of addiction (primarily alcohol) in collaboration with the Obesity group. This program resulted in 4 clinic candidates, the most advanced of which entered phase 3. The team also generated data which supported an interest in cognition enhancement as a possible additional indication (with the potential for treatment of symptoms both in AD and schizophrenia). Following on from the CB1 cognition work he moved more in depth towards the psychosis disease space serving as the Research Portfolio Lead on a 5HT2C agonist program which also generated a clinical candidate. Phil joined the CNS management team in 2004 and subsequently became chair of the Schizophrenia Disease Focus team and served as biology contact on the Development Team. In 2009 he became the head of the neuroscience Best In Class Unit which served programs across both neurology and psychiatry followed by an appointment is as head of the neurology group with a major focus on programs in Alzheimer's and Parkinson's Disease areas. In 2011 he took on a new role as head of Neuro Opportunities leading the strategy for external collaborations, in licensing and portfolio partnering. His current position as Head Of Business Research expands the remit to include all of the budget and fiscal oversight for the Neuroscience and Pain research unit as well as the remit of executing on and building an external portfolio.
Connect with Phil:
Michal Preminger, Ph.D., MBA | | Executive Director, Harvard University Office of Technology Development
Dr. Michal Preminger is currently Executive Director at Harvard University's Office of Technology Development, overseeing industry partnerships, startup formation and development of scientific programs and discoveries emerging from research at Harvard Medical School. Prior to joining Harvard in 2005, she held a number of business development and technology development positions in the biotech and hi-tech industries, most recently as Vice President of Protein Therapeutics at Compugen, responsible for the business management of the company's emerging drug discovery pipeline and, previously, as Director of Marketing and Business Development at Lucent Technologies. Dr. Preminger also co-founded a startup company and has been serving on the boards and scientific advisory boards of several not-for-profit, biotech, and medical device companies. Dr. Preminger holds an undergraduate degree in Medicine from the Hebrew University School of Medicine, M.Sc. and Ph.D. from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.
Connect with Michal:
Jeffrey Nye, M.D., Ph.D. | | Vice President Neuroscience Innovation and Scientific Partnership Strategy, Johnson & Johnson Innovation
Jeff is Vice President of Neuroscience Innovation and Scientific Partnership Strategy at the Johnson & Johnson Innovation, Boston. Jeff is responsible for external R&D in neuroscience, focusing on novel business relationships, venture, academic, public-private partnerships and risk-shared outsourcing.
Previously, Jeff was Chief Medical Officer of the East Coast Research and Early Development unit and was responsible for early programs across all therapeutic areas. Prior roles include VP of Experimental Medicine, and leader of programs for Galantamine for Alzheimer's disease, and Topamax for epilepsy and migraine. He previously served as a Director of CNS Discovery Genomics and Biotechnology at Pharmacia. Prior to joining industry, Jeff was a tenured associate professor of Molecular Pharmacology, Biological Chemistry and Pediatrics (Neurology) at Northwestern University. He has a BA and MA from Harvard, and a MD and PhD (with Solomon Snyder) from the Johns Hopkins University School of Medicine. He served as resident, postdoctoral fellow (with Richard Axel) and assistant professor of Pediatrics in Neurology at the College of Physicians and Surgeons of Columbia University.
Jeff has published over 60 papers on basic and clinical research, and has led pharma programs in discovery through clinical development. He has served on study sections and advisory panels, and currently serves as a Councilor of the British Association of Psychopharmacology, Advisory panels for the Allen Institute, Project UROK and the Prize4Life an ALS foundation.
Connect with Jeff: